PULMOTECT’S MANAGEMENT TEAM includes the lead inventors of the technology as well as experienced business leaders. In collaboration with leading academic institutions, this team is well positioned to achieve key milestones and transition our products from the clinic to the market.
Colin Broom, BSc, MB BS, MRCP, FFPM
Dr. Broom has been our CEO since September 2019. Over the past 30 years he has been involved in all stages of drug development and commercialization across multiple therapeutic areas including oncology, anti-infectives and pulmonary medicine. He served as CEO of Nabriva Therapeutics plc until July 2018 and remains a member of the Board of Directors. Previously he was Chief Scientific Officer at ViroPharma Inc. until its acquisition by Shire in 2014 and was a member of the Board of NPS Pharmaceuticals. Previous positions include a range of international leadership roles with Amgen, SmithKline Beecham and Glaxo (now Glaxo SmithKline). He has a BSc in Pharmacology from University College, London and received his medical degree and clinical training at St George’s Hospital Medical School in London. He is a member of the Royal College of Physicians of the UK and a fellow of the Faculty of Pharmaceutical Medicine.
BRENTON SCOTT, PHD
President and Chief Operating Officer
Dr. Scott is a co-founder of the company and has helped lead the initial technology out of the lab and into the clinic. Prior to his industry role, his academic experience focused on vesicular traffic, airway inflammation and infection. He serves as the PI on multiple grant awards, including the Cancer Prevention Research Institute of Texas (CPRIT) and Texas Emerging Technology Fund (TETF) awards from the State of Texas and seven Small Business Innovative Research (SBIR) awards. He is a regular reviewer of SBIR grant applications for the NIH. He concurrently received his PhD in Biochemistry and Cell Biology from Rice University and his MBA from University of Houston.
ATUL VARADHACHARY, MD, PHD
Chief Medical Officer
A Director of Pulmotect and the Managing Partner of Fannin Innovation Studio. Dr. Varadhachary brings over two decades of experience in life sciences and healthcare in both corporate and entrepreneurial settings. Previously he served as President of U.S. Operations at Reliance Life Sciences (RLS), part of the Reliance Group, India’s largest private sector enterprise with over $64 billion in annual revenues and for nine years as President & COO of Agennix, Inc., a late-stage biotechnology company where he helped lead a successful sale of the company. He also served as Senior Engagement Manager at the global management consulting firm, McKinsey & Co. He has served on the Board of Managers of the Harris Health System and as an Adjunct Professor at the Baylor College of Medicine and at the Jones Graduate School of Management at Rice University. He serves on the Life Sciences Advisory Committee of the Houston Technology Center, on the board of Reliance Life Sciences. and has served on the University of Houston Biotechnology Industrial Advisory Committee.
JOHN SCHAUMBERG, PhD
Head, Clinical Operations
Dr. Schaumberg has more than 30 years of drug development expertise, including experience with global pharmaceutical organizations, biotechnology companies and clinical research organizations. His past roles include Vice President level positions in Biotech as Senior Vice President, Clinical Operations of Agennix AG as well as Vice President level positions in the clinical research organizations PRA International and Inveresk. Prior to Inveresk, he held a variety of clinical development and project management roles with Glaxo, Parke-Davis and Valentis. While at Glaxo, he was involved in the clinical development programs of Serevent®, a long acting beta agonist, and Flovent®, an inhaled corticosteroid, for the treatment of asthma. Dr. Schaumberg received his Ph.D. from the University of Iowa (U.S.) in Medicinal Chemistry and Natural Products, and his Bachelor of Pharmacy from Washington State University (U.S.).
Anoshie Ratnayake, MD
Dr. Ratnayake brings over 12 years of leadership experience in clinical research and drug development. She has provided strategic guidance for early phase drug development, including for several novel pulmonary, allergy, asthma, and immunomodulating drugs. She received her bachelor’s degree (BA) from Stanford University, MD from University of Southern California (USC) Keck School of Medicine, and MPH from Harvard University. She completed postgraduate training at University of Texas Southwestern Medical Center, allergy/Immunology fellowship training at USC, and practiced as an allergist and immunologist for over 9 years.
Rena Johnson, PHD
Dr. Rena Johnson is a Project Manager at Pulmotect. She joined the company in May 2018. Dr. Johnson received her Ph.D. in Biology from the University of Kiel, Germany in 2011. She moved to the US for a postdoctoral training at the Center for Lung Biology at the University of Washington, Seattle and at the Women’s Guild Lung Institute at Cedars-Sinai Medical Center, Los Angeles with Dr. Peter Chen. During her postdoctoral training, her research focused on the role of the lung epithelium in acute lung injury, especially in the response to influenza infection with particular interest in the role of syndecan-1, the major proteoglycan expressed by epithelial cells in the lung. She has strong interest in translating innovation from the lab bench to novel bio-medical solutions that can ultimately improve patient’s health.